- Home
- COEP vs CGTX Comparison
COEP vs CGTX Comparison
Compare COEP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COEP | CGTX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | COEP | CGTX |
|---|---|---|
| Price | $15.70 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 74.3K | ★ 978.2K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,996.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $0.22 |
| 52 Week High | $21.41 | $3.83 |
Technical Indicators
Market Signals| Indicator | COEP | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 54.36 |
| Support Level | $15.40 | $1.58 |
| Resistance Level | $16.80 | $1.81 |
| Average True Range (ATR) | 1.57 | 0.13 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 20.64 | 82.30 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.